We believe Orexo’s Q315 financial results are solid, with revenues just below but profits ahead of the trends implied by our 2015 forecasts. There have been a number of positive developments during Q315 that should help drive mid- to long-term Zubsolv sales. These include a steadily growing market share, an expanded Zubsolv label, new PBM agreements to offset the CVS loss, and important initial steps by the US government to increase access to treatment, which could substantially increas
22 Oct 2015
Zubsolv makes key gains in Q3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Zubsolv makes key gains in Q3
We believe Orexo’s Q315 financial results are solid, with revenues just below but profits ahead of the trends implied by our 2015 forecasts. There have been a number of positive developments during Q315 that should help drive mid- to long-term Zubsolv sales. These include a steadily growing market share, an expanded Zubsolv label, new PBM agreements to offset the CVS loss, and important initial steps by the US government to increase access to treatment, which could substantially increas